Medical Policies - Medicine


Acoustic Respiratory Management (ARM)

Number:MED201.037

Effective Date:10-15-2017

Coverage:

*CAREFULLY CHECK STATE REGULATIONS AND/OR THE MEMBER CONTRACT*

Acoustic respiratory management (ARM), including the measurement, recording and interpretation of data, is considered experimental, investigational and/or unproven for the diagnosis and/or management of asthma, chronic cough and other respiratory disorders.

Description:

Acoustic respiratory management (ARM) is a method to record breath sounds and document wheeze rate measurements and cough for the diagnosis and/or management of asthma, chronic cough and other respiratory disorders. ARM is noted to evaluate the wheeze rate during broncho-dilatation, wheeze reversibility and bronchial challenge testing. ARM may also include the continuous measurement during emergencies, ambulatory evaluation for wheeze and cough, and sleep testing to verify the symptoms of nocturnal asthma and cough-variant asthma. ARM is noted to be useful for patients who cannot perform currently available lung function tests.

Respiri Limited (ASH: RSH) previously known as iSonea Ltd. and KarmelSonix Ltd. (ASX: KSX) is promoting the AirSonea product, which builds on the company's previous device, the Wheezometer. The AirSonea uses a proprietary sensing method the company defines as acoustic respiratory monitoring. This method of monitoring measures a patient's wheeze rate before and after tests with a bronchodilator to demonstrate the effectiveness of asthma treatments.

The AirSonea (previously known as the WheezoMeter) is handheld for clinical or home use and acts much like a stethoscope a physician uses when listening to a patient’s lungs. By placing the sensor on the trachea [windpipe] for 30 seconds of normal breathing, the device can record and then analyze breath sounds for the presence of wheezing. The recorded breath sounds are analyzed with advanced algorithms to detect, quantify and measure wheeze, an important sign of air flow obstruction in asthma. This product is currently unavailable for sale in the United States.

Rationale:

A search of peer reviewed literature conducted through July 2016 identified no current studies or active clinical trial publications to evaluate the efficacy of acoustic respiratory management for the diagnosis and/or management of asthma, chronic cough and other respiratory disorders.

AirSonea Wheeze Detection Study (NCT01927172) was the only study identified on ClinicalTrials.gov, specific to acoustic respiratory management (ARM), which was last updated August 2013 with the following “The recruitment status of this study is unknown because the information has not been verified recently. No additional information identified.

Contract:

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

Coding:

CODING:

Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT/HCPCS/ICD-9/ICD-10 Codes

The following codes may be applicable to this Medical policy and may not be all inclusive.

CPT Codes

94799

HCPCS Codes

None

ICD-9 Diagnosis Codes

Refer to the ICD-9-CM manual

ICD-9 Procedure Codes

Refer to the ICD-9-CM manual

ICD-10 Diagnosis Codes

Refer to the ICD-10-CM manual

ICD-10 Procedure Codes

Refer to the ICD-10-CM manual


Medicare Coverage:

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <http://www.cms.hhs.gov>.

References:

1. Manufacturer Product Information. AirSonea® FAQ. Available at: <www.respiri.com>

2. U.S. National Institutes of Health/Clinical Trials. AirSonea Wheeze Detection Study (NCT01927172). Available at: <www.http://clinicaltrials.gov>, (accessed August 2016).

Policy History:

DateReason
10/15/2017 Reviewed. No changes.
10/1/2016 Document updated with literature review. Coverage unchanged.
7/1/2015 Reviewed. No changes.
10/1/2014 Document updated with literature review. Coverage unchanged.
5/1/2011 New medical document. Acoustic respiratory management (ARM), including the measurement, recording and interpretation of data is considered experimental, investigational and unproven for the diagnosis and/or management of asthma, chronic cough and other respiratory disorders.
1/1/2011 New position statement. Acoustic respiratory management (ARM), including the measurement, recording and interpretation of data is considered experimental, investigational and unproven for the diagnosis and/or management of asthma, chronic cough and other respiratory disorders.

Archived Document(s):

Back to Top